Ixazomib plus lenalidomide compared to ixazomib alone for myeloma maintenance
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial studies whether adding low-dose lenalidomide to ixazomib can help keep high-risk multiple myeloma from coming back after initial treatment. It may help prolong the time before the disease worsens, while also checking side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have multiple myeloma that is causing symptoms, and it has “high-risk” genetic features (like 17p deletion, TP53 mutation, or certain chromosome changes).
- You’ve finished initial treatment called VRD (bortezomib/ixazomib, lenalidomide, dexamethasone) and consolidation, and you plan to start maintenance therapy.
- Your general health is good enough for study treatment (ECOG 0 to 3).
- You’re expected to live more than 6 months and are between 18 and 80 years old.
- Your organs can handle treatment: kidneys, liver, lungs, and heart tests must meet safety limits.
- You can follow the study plan and sign informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether adding ixazomib (an oral drug) to a transplant using your own stem cells can control relapsed multiple myeloma better. It may help by strengthening anti-myeloma treatment after the transplant, aiming to delay disease progression.
This Phase 2 trial tests whether adding isatuximab and lenalidomide as long-term treatment after stem cell transplant can help keep high-risk multiple myeloma under control. It may help some people reduce the chance of the disease coming back after transplant.
This trial tests whether adding teclistamab to lenalidomide (or using teclistamab alone) helps keep newly diagnosed multiple myeloma from coming back after an autologous stem cell transplant. It’s comparing these options to lenalidomide alone as long-term maintenance.
This trial tests two treatments (lenalidomide plus elranatamab versus lenalidomide plus daratumumab) as maintenance therapy after a stem cell transplant for multiple myeloma. The goal is to see which combination is better at keeping the cancer in remission.
This Phase 2 study tests whether adding isatuximab and lenalidomide after an autologous stem cell transplant can keep multiple myeloma from coming back when tests show leftover (minimal) disease. If it works, it may improve how long you stay in response.
This trial tests a combination of study drugs as the first treatment for newly diagnosed multiple myeloma, followed by maintenance based on your risk and response. It aims to improve outcomes while allowing some patients to postpone or avoid a stem cell transplant.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.